Aurora Cannabis Reports 9% Q1 Revenue YoY Decline As International Medical Sales Grow 17%

Canadian medical cannabis giant Aurora Cannabis Inc. (NASDAQ: ACB) (TSX: ACB) announced on Wednesday that its first-quarter revenue declined 9% year-over-year to CA67.6 million ($48.2 million).

Medical cannabis sales dropped 1% over the same period to CA$64 million. International medical revenue climbed 17% to CA$43.3 million on strong demand in Germany. The management said it continues to invest in EU-GMP production capacity to support expanding demand in Europe.

Canadian medical sales fell 25% to CA$20.7 million due to lower federal reimbursement rates.

Consumer cannabis revenue decreased to CA$2.1 million from CA$7.9 million as Aurora Cannabis advances its planned exit from the segment.

“We remain confident in our commercial execution, supported by our genetics program and regulatory and operational expertise which underpin our leadership in Canada, Germany, Poland, Australia, and New Zealand,” Miguel Martin, executive chairman and CEO, said in a press release. “These competitive advantages support our strategy to invest further in EU-GMP manufacturing capacity so that we can supply growing international markets for medical cannabis and thereby maintain and expand our market share.”

Q1 2027 Financial Highlights

• Adjusted EBITDA came in positive at CA$3.4 million. That’s down from CA$10.8 million in the prior year’s period.
• Adjusted gross margin declined year-over-year from 64% to 58%.
• Adjusted net income was CA$3.8 million, representing a decrease from CA$6.6 million in the first quarter of fiscal 2026.
• Net loss from continuing operations totaled CA$4 million, representing an improvement from a CA$10.2 million loss in the prior year’s period.
• Free cash flow fell to negative CA$5.8 million, compared with positive CA$6.8 million in the corresponding quarter of fiscal 2026.
• Aurora Cannabis said it has maintained a strong balance sheet with $149.1 million of cash, cash equivalents and short-term investments with no debt.

ACB Price Action

Aurora Cannabis’ shares traded 0.71% lower at $2.79 per share at the time of writing on Wednesday.